Chemoinformaics analysis of (11E,13Z)-Labdadien-8-ol
| Molecular Weight | 290.491 | nRot | 2 |
| Heavy Atom Molecular Weight | 256.219 | nRig | 13 |
| Exact Molecular Weight | 290.261 | nRing | 2 |
| Solubility: LogS | -4.717 | nHRing | 0 |
| Solubility: LogP | 4.817 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 55 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 21 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 34 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 56.873 |
| nHD | 1 | BPOL | 34.109 |
| QED | 0.665 |
| Synth | 4.307 |
| Natural Product Likeliness | 3.023 |
| NR-PPAR-gamma | 0.012 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.336 |
| Pgp-sub | 0 |
| HIA | 0.009 |
| CACO-2 | -4.549 |
| MDCK | 0.0000142 |
| BBB | 0.107 |
| PPB | 0.964664 |
| VDSS | 0.848 |
| FU | 0.0455131 |
| CYP1A2-inh | 0.1 |
| CYP1A2-sub | 0.68 |
| CYP2c19-inh | 0.419 |
| CYP2c19-sub | 0.942 |
| CYP2c9-inh | 0.285 |
| CYP2c9-sub | 0.946 |
| CYP2d6-inh | 0.759 |
| CYP2d6-sub | 0.894 |
| CYP3a4-inh | 0.667 |
| CYP3a4-sub | 0.591 |
| CL | 11.702 |
| T12 | 0.142 |
| hERG | 0.018 |
| Ames | 0.005 |
| ROA | 0.029 |
| SkinSen | 0.144 |
| Carcinogencity | 0.018 |
| EI | 0.829 |
| Respiratory | 0.929 |
| NR-Aromatase | 0.024 |
| Antiviral | No |
| Prediction | 0.727744 |